Overview

Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer

Status:
Recruiting

Trial end date:
2034-04-01

Target enrollment:

Participant gender:

Summary

The investigators are conducting this study with men that have prostate cancer and are getting standard of care treatment with the drugs abiraterone acetate and prednisone. The study will follow men with prostate cancer from initiation of participation in the study and for up to 10 years. The reason for the study is that researchers think that there may be a connection between the race and ethnicity of men with prostate cancer and how well the standard treatments work for the participants.

Phase:

Phase 2

Details

Lead Sponsor:

Martha Mims

Treatments:

Abiraterone Acetate
Hormones
Prednisone